| NCT ID | NCT06550206 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California Santa Cruz |
| Condition | Social Behavior |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-07-30 |
| Primary Completion | 2025-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-07-30 with a primary completion date of 2025-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will assess if toddlers show differences in stranger wariness according to race, temperament, social network diversity, and neighborhood diversity.
Eligibility Criteria
Inclusion Criteria: * typically developing * age 13-24 months Exclusion Criteria: \- any known developmental delays
Contact & Investigator
Hyesung Hwang, PhD
PRINCIPAL INVESTIGATOR
University of California Santa Cruz
Frequently Asked Questions
Who can join the NCT06550206 clinical trial?
This trial is open to participants of all sexes, aged 13 Months or older, up to 24 Months, studying Social Behavior. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06550206 currently recruiting?
Yes, NCT06550206 is actively recruiting participants. Contact the research team at serjuare@ucsc.edu for enrollment information.
Where is the NCT06550206 trial being conducted?
This trial is being conducted at Santa Cruz, United States.
Who is sponsoring the NCT06550206 clinical trial?
NCT06550206 is sponsored by University of California Santa Cruz. The principal investigator is Hyesung Hwang, PhD at University of California Santa Cruz. The trial plans to enroll 100 participants.